Celgene Sues Natco To Block Generic Revlimid

Law360, New York (October 13, 2010, 3:58 PM EDT) -- Celgene Corp. has slapped India's Natco Pharma Ltd. with a patent infringement lawsuit in an effort to keep a generic version of its top-selling drug Revlimid off the market.

New Jersey-based Celgene lodged a complaint Friday in the U.S. District Court for the District of New Jersey, following Natco's filing of an abbreviated new drug application seeking the U.S. Food and Drug Administration's approval for a copycat version of Revlimid.

The complaint alleges that Natco has teamed up with an unknown partner, which Natco's counsel declined...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

CELGENE CORPORATION v. NATCO PHARMA LIMITED


Case Number

2:10-cv-05197

Court

New Jersey

Nature of Suit

Patent

Judge

Susan D. Wigenton

Date Filed

October 8, 2010

Law Firms

Companies

Government Agencies

Patents